Efficacy of ceftobiprole in intensive care unit (ICU) patients with hospital-acquired pneumonia (HAP)

T. Welte, Thomas Scheeren, Alejandro H. Rodriguez, A. Demange, Marc Engelhardt

Research output: Contribution to conferenceAbstractAcademic


Introduction: Ceftobiprole medocaril is a novel cephalosporin approved in Europe for the treatment of hospital-acquired pneumonia (HAP) excluding ventilator-associated pneumonia (VAP). Ceftobiprole exhibits broad bactericidal activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.

Methods: A subgroup analysis was performed from a large multinational, double-blind, randomised study (NCT00210964) in patients with HAP (excluding VAP) who were in the ICU at randomization. Ceftobiprole (500 mg three times daily (tid)) was compared to ceftazidime (2000 mg tid) and linezolid (600 mg twice daily), intravenously for 7-14 days. Primary endpoint was the clinical cure rate at the test-of-cure (TOC) visit (7-14 days after end of treatment).

Results: In the intent-to-treat (ITT) analysis set, a subgroup of 219/571 (38%) were ICU patients. 29/219 (13%) patients had baseline bacteraemia. 154/219 (70%) patients had a valid baseline pathogen (respiratory specimen and/or blood culture), 28/154 (18%) presented with MRSA and 23/154 (15%) with P. aeruginosa.

Conclusion: In HAP (excluding VAP) patients treated in the ICU, the efficacy of ceftobiprole was demonstrated in comparison to combined ceftazidime/linezolid treatment, including patients with bacteraemia, MRSA and/or pseudomonal infections at baseline.
Original languageEnglish
Publication statusPublished - 10-Sept-2014
EventEuropean-Respiratory-Society (ERS) International Congress - Milan, Italy
Duration: 9-Sept-201713-Sept-2017


ConferenceEuropean-Respiratory-Society (ERS) International Congress
Internet address

Cite this